^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

irinotecan hydrochloride liposome injection (HR070803)

i
Other names: HR070803
Associations
Trials
Company:
Jiangsu Hengrui Pharma
Drug class:
Topoisomerase I inhibitor
Related drugs:
Associations
Trials
13d
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer (clinicaltrials.gov)
P2, N=120, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
New P2 trial • Combination therapy
|
5-fluorouracil • leucovorin calcium • Teysuno (gimeracil/oteracil/tegafur) • Onivyde (nanoliposomal irinotecan) • irinotecan hydrochloride liposome injection (HR070803)
4ms
New P3 trial • Combination therapy
|
gemcitabine • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • irinotecan hydrochloride liposome injection (HR070803)
10ms
New P2/3 trial • Combination therapy • Metastases
|
Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • irinotecan hydrochloride liposome injection (HR070803)
10ms
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov)
P3, N=522, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • irinotecan hydrochloride liposome injection (HR070803)